High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis
- PMID: 23089040
- PMCID: PMC3780595
- DOI: 10.1016/j.ijid.2012.08.005
High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis
Abstract
Background: Patients with methicillin-resistant Staphylococcus aureus (MRSA) infections caused by isolates with a high but 'susceptible' minimum inhibitory concentration (MIC) to vancomycin may suffer poor outcomes. The aim of this study was to determine the association of high compared to low vancomycin MICs and clinical outcomes (treatment failure and mortality) in patients with MRSA infections.
Methods: PubMed, the Cochrane Library, and electronic abstracts from meetings were queried from January 2000 to July 2010. Two reviewers independently screened titles and abstracts of studies evaluating outcomes of patients with MRSA infections, using broth microdilution (BMD) or the Etest to determine MIC, for full-text review. Patients participating in included studies were classified into two mutually exclusive groups: high MIC or low MIC. High MIC was defined as MIC ≥1mg/l by BMD or ≥1.5mg/l by Etest. Study-defined failure and mortality were assessed in each group.
Results: Fourteen publications and six electronic abstracts met the inclusion criteria, with 2439 patients (1492 high MIC and 947 low MIC). There was no evidence of publication bias or heterogeneity. An increased risk of failure was observed in the high MIC group compared to the low MIC group (summary risk ratio (RR) 1.40, 95% confidence interval (CI) 1.15-1.71). The overall mortality risk was greater in the high MIC group than in the low MIC group (summary RR 1.42, 95% CI 1.08-1.87). Sensitivity analyses showed similar findings for failure (summary RR 1.37, 95% CI 1.09-1.73) and mortality (summary RR 1.46, 95% CI 1.06-2.01) for patients with bacteremia. The study quality was poor-to-moderate, and study-defined endpoints were variable.
Conclusions: A susceptible but high MIC to vancomycin is associated with increased mortality and treatment failure among patients with MRSA infections.
Copyright © 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Figures




Similar articles
-
Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.Int J Antimicrob Agents. 2015 Dec;46(6):689-95. doi: 10.1016/j.ijantimicag.2015.09.010. Epub 2015 Oct 17. Int J Antimicrob Agents. 2015. PMID: 26555059
-
Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.Antimicrob Agents Chemother. 2016 Sep 23;60(10):5841-8. doi: 10.1128/AAC.00227-16. Print 2016 Oct. Antimicrob Agents Chemother. 2016. PMID: 27431221 Free PMC article. Clinical Trial.
-
Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.J Infect. 2017 Mar;74(3):248-259. doi: 10.1016/j.jinf.2016.12.007. Epub 2016 Dec 22. J Infect. 2017. PMID: 28017826
-
Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis.Infection. 2021 Oct;49(5):803-811. doi: 10.1007/s15010-020-01568-4. Epub 2021 Jan 4. Infection. 2021. PMID: 33394368 Review.
-
The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.Clin Infect Dis. 2012 Mar;54(6):755-71. doi: 10.1093/cid/cir935. Epub 2012 Feb 2. Clin Infect Dis. 2012. PMID: 22302374
Cited by
-
Optimizing the detection of methicillin-resistant Staphylococcus aureus with elevated vancomycin minimum inhibitory concentrations within the susceptible range.Infect Drug Resist. 2016 May 31;9:87-92. doi: 10.2147/IDR.S107961. eCollection 2016. Infect Drug Resist. 2016. PMID: 27330319 Free PMC article.
-
The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis.BMC Res Notes. 2016 Sep 29;9(1):455. doi: 10.1186/s13104-016-2252-7. BMC Res Notes. 2016. PMID: 27686168 Free PMC article.
-
Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.Eur J Clin Microbiol Infect Dis. 2019 May;38(5):903-912. doi: 10.1007/s10096-019-03500-7. Epub 2019 Feb 6. Eur J Clin Microbiol Infect Dis. 2019. PMID: 30729396
-
Discordance of vancomycin minimum inhibitory concentration for methicillin-resistant Staphylococcus aureus at 2 μg/mL between Vitek II, E-test, and Broth Microdilution.PeerJ. 2020 May 11;8:e8963. doi: 10.7717/peerj.8963. eCollection 2020. PeerJ. 2020. PMID: 32435531 Free PMC article.
-
Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital.Microb Drug Resist. 2015 Feb;21(1):25-34. doi: 10.1089/mdr.2014.0190. Epub 2014 Dec 23. Microb Drug Resist. 2015. PMID: 25535825 Free PMC article.
References
-
- Moellering RC., Jr Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006;42(Suppl 1):S3–4. - PubMed
-
- Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 1998;351:1212. - PubMed
-
- US Centers for Disease Control and Prevention . CDC reminds clinical laboratories and healthcare infection preventionists of their role in the search and containment of vancomycin-resistant Staphylococcus aureus (VRSA) CDC; Atlanta, GA: [accessed April 24, 2011]. 2011. Available at: http://www.cdc.gov/HAI/settings/lab/vrsa_lab_search_containment.html.
-
- Clinical and Laboratory Standards Institute . Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S16. CLSI; Wayne, PA: 2006.
-
- Tenover FC, Moellering RC., Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44:1208–15. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous